Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment

MT Newswires Live

05/30

Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.

The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.

The company anticipates receiving the milestone payment from Fuso within 30 days.

Shares rose nearly 2% in morning trade Friday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539905282"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539905282\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539905282?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 09:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539905282","market":"us","top_or_hot":-1,"title":"Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.</p><p>The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.</p><p>The company anticipates receiving the milestone payment from Fuso within 30 days.</p><p>Shares rose nearly 2% in morning trade Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Confirms First Japan Clinical Trial Site Open for Recruitment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-05-30 09:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.</p><p>The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.</p><p>The company anticipates receiving the milestone payment from Fuso within 30 days.</p><p>Shares rose nearly 2% in morning trade Friday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"醫藥生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2539905282","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539905282","pubTimestamp":1748566849,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.The company anticipates receiving the milestone payment from Fuso within 30 days.Shares rose nearly 2% in morning trade Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7501":"新冠治疗股","BK7067":"生物科技","DXB.AU":"DIMERIX LTD"},"translate_title":"Dimerix确认首个日本临床试验中心开放招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":0.9},"content_text":"Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.The company anticipates receiving the milestone payment from Fuso within 30 days.Shares rose nearly 2% in morning trade Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}